This issue becomes even more relevant considering that attempts to target CSCs population are actively ongoing, and a chimeric molecule combining the murine anti-human CD133 and the cytotoxic drug monomethyl auristatin has been already shown to be able to inhibit the growth of gastric and hepatocellular cancer cells in vitro and in vivo [34]. The gene discussed is PROM1; the disease is hepatocellular carcinoma.